As 2025 comes to a close, we’re reflecting on a year that moved RetinaLyze forward in ways that matter: better science, stronger clinical tools, deeper integrations, and broader access to eye screening around the world.
Our mission remains unchanged – to make early, safe and accessible eye-disease detection a reality for everyone – but the past year brought us closer to that goal than ever before.
Advancing Glaucoma Assessment: Fundus + Perimetry in One View
A major highlight of 2025 was the evolution of RetinaLyze Advanced Glaucoma.
We introduced built-in perimetry analysis, allowing clinicians to combine structural fundus insights with functional visual-field results inside the same workflow.
Compatibility now includes:
Haag-Streit Octopus (TOP)
OCULUS (SPARK)
ZEISS Humphrey (SITA)
With this step, indices like GDF, MD, PSD/sLV – and the new TCV index – come together to deliver a more complete, more comparable assessment of each patient’s ocular health.
Scientific Insights That Change How We See Glaucoma
2025 was also the year that new research challenged long-standing assumptions.
A study published in Archivos de la Sociedad Española de Oftalmología examined more than 365,000 normal optic nerves analysed with RetinaLyze. The findings showed just how strongly optic-disc size influences what we consider “normal” cup-to-disc ratio and why many high CDR values are physiological, not pathological.
This work provided clinicians with a clearer nomogram for interpreting ambiguous cases and led to a more refined, more specific version of the Globin Discriminant Function (GDF).
The revised method was validated on both normal and confirmed glaucoma cases.
Our ONH Hb methodology also gained strong validation in Scientific Reports. The study confirmed the relationship between hemoglobin patterns, RNFL/GCL thickness, and visual-field performance – reinforcing the role of colorimetric analysis in large-scale, cost-efficient glaucoma detection.
Growing Recognition of Our 2021 Glaucoma Framework
Our foundational 2021 publication continued to gain traction, becoming a reference point for how deep-learning–based colorimetric analysis can integrate with OCT and perimetry for scalable glaucoma assessment.
By mid-2025, the paper had accumulated thousands of views and strong citation growth across Crossref, WOS and Scopus – a signal that AI-supported glaucoma detection is entering mainstream clinical dialogue.
A Year of Expansion: Integrations and Partnerships
2025 also strengthened RetinaLyze’s global reach.
New integrations
A deep collaboration with Medibrix, improving data connectivity and workflow automation.
Integration with new devices such as Huvitz HFC-1 and HOCT-1F.
Webinar and HEYEX Appway integrations together with Heidelberg Engineering.
New and strengthened distribution partnerships
Medicontur CZ (Czech Republic)
Surveye (Slovakia)
Romger (Romania)
Bloss (Spain)
Eyevinci (Netherlands)
Rockmed (Netherlands, Belgium, Luxembourg)
FE-Group (Italy)
Ongoing strong activity in Brazil, now supported by Prof. Dr. Roberto Lauande Pimentel
Together, these partnerships are making AI screening more accessible across Europe and Latin America.
Clinical adoption and public health impact
One of the most meaningful highlights came from Aalborg University’s Center for General Practice.
In a real-world study involving ~300 participants, researchers found that AI-assisted diabetic retinopathy screening in general practice successfully reached patients who typically miss standard screening. Participants also reported high acceptance – as long as human oversight remained part of the process.
The takeaway is clear: Accessible screening increases participation, and participation leads to earlier detection.
A strong global presence
This year, RetinaLyze contributed to scientific and industry dialogue at major events including:
ESCRS 2025
EURETINA 2025
The Romanian Society of Ophthalmology (SRO) Annual Meeting
Several Danish–LATAM Health Alliance delegations and webinars
These interactions deepened connections between clinicians, researchers, manufacturers and health-system leaders and brought valuable feedback that continues to inform the platform.
What’s coming in 2026
While 2025 delivered major steps forward, 2026 is shaping up to be even more transformative.
We are preparing:
1. 3D ONH morphology from 2D fundus images
A leap in structural interpretation bringing near-OCT insights without requiring OCT hardware.
2. A new PDF reporting experience
More intuitive clinical explanations and visuals, designed to help clinicians communicate results clearly to patients and referring colleagues.
Closing the year with momentum
2025 was a year defined by scientific progress, practical innovation, stronger partnerships and greater clinical adoption.
As we move into 2026, we remain committed to supporting clinicians, enabling earlier detection and making high-quality eye screening available everywhere from specialist clinics to primary care, from large hospitals to rural communities.
To all our partners, clinicians, researchers, distributors, and collaborators around the world: thank you. Together, we are shaping the future of eye care.